The Death of Cancer: Book Review and Reflections

By CHADI NABHAN MD, MBA, FACP Some books draw you in based on a catchy title, a provocative book jacket, or familiarity with the author. For me, recollections of medical school primers written by the renowned lymphoma pioneer Vincent DeVita Jr. and my own path as an oncologist immediately attracted me to “The Death of Cancer.” I felt a connection to this book before even reading it and prepped myself for an optimistic message about how the cancer field is moving forward. Did I get what I bargained for? Co-authored with his daughter, Elizabeth DeVita-Raeburn, DeVita brings us back decades ago to when he had just started at the National Cancer Institute (NCI) under the wings of Jay Freireich and Tom Frei. At the time, he was a clinical associate and a “chemotherapist”; the field was ultimately renamed and defined as medical oncology. (Note to self: I am ecstatic the field was renamed; I would prefer to be called a medical oncologist anytime than a chemotherapist, but that’s just me). He recounts how chemotherapy was frowned upon in favor of the two preferable ways to treat cancer at the time: surgery and radiotherapy. DeVita eloquently describes how his mentors were ridiculed when they announced their pursuit to cure childhood leukemia using combination chemotherapy; their approach and determination provided him with inspiration to push his research further. He goes on to describe in a fascinating manner the way he designed the MOPP regimen, which...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Health Care Books Physicians Book Review Chadi Nabhan Chemotherapy Oncology randomized controlled trials The Death of Cancer Vincent DeVita Source Type: blogs

Related Links:

The interleukin-3 receptor α subunit, CD123, is expressed in many hematologic malignancies including acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). Tagraxofusp (SL-401) is a CD123-targeted therapy consisting of interleukin-3 fused to a truncated diphtheria toxin payload. Factors influencing response to tagraxofusp other than CD123 expression are largely unknown. We interrogated tagraxofusp resistance in patients and experimental models and found that it was not associated with CD123 loss. Rather, resistant AML and BPDCN cells frequently acquired deficiencies in the diphthamide ...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
The interleukin 3 receptor (CD123) is a transmembrane protein that is absent or hardly expressed on normal hematopoietic stem cells, but highly expressed on the surface of cancer cells in several hematologic malignancies. In this issue of the JCI, Togami et al. investigated the mechanism of resistance to the recently approved anti-CD123 agent tagraxofusp, which consists of interleukin 3 fused to a truncated diphtheria toxin (DT) molecule. The authors demonstrated that loss of the intracellular target for DT, diphthamide, a conservative modification of histidine 715 in eukaryotic elongation factor 2, resulted in tagraxofusp...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
CONCLUSION These observations demonstrate that immune control following ACT requires significant repertoire remodeling, which may be impaired in nonresponders because of the preexisting immune environment. Immunological interventions that can modulate this environment may improve clinical outcomes.TRIAL REGISTRATION Australian New Zealand Clinical Trial Registry, ACTRN12613000981729.FUNDING This study was supported by funding from the National Health and Medical Research Council, Australia (APP1132519 and APP1062074).
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Tumor-resident lymphocytes can mount a response against neoantigens expressed in microsatellite-stable gastrointestinal (GI) cancers, and adoptive transfer of neoantigen-specific lymphocytes has demonstrated antitumor activity in selected patients. However, whether peripheral blood could be used as an alternative minimally invasive source to identify lymphocytes targeting neoantigens in patients with GI cancer with relatively low mutation burden is unclear. We used a personalized high-throughput screening strategy to investigate whether PD-1 expression in peripheral blood could be used to identify CD8+ or CD4+ lymphocytes ...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Conclusion: Nontransporting emergency medical service vehicles have the potential for inclusion in the extracorporeal membrane oxygenation network of the study area.
Source: Revista Brasileira de Terapia Intensiva - Category: Intensive Care Source Type: research
ABSTRACT Objective: Preoperative functional evaluation is central to optimizing the identification of patients with non-small cell lung cancer (NSCLC) who are candidates for surgery. The minute ventilation/carbon dioxide output (VE/VCO2) slope has proven to be a predictor of surgical complications and mortality. Pulmonary rehabilitation programs (PRPs) could influence short-term outcomes in patients with COPD undergoing lung resection. Our objective was to evaluate the effects of a PRP on the VE/VCO2 slope in a cohort of patients with COPD undergoing lung resection for NSCLC. Methods: We retrospectively evaluated 25 consec...
Source: Jornal Brasileiro de Pneumologia - Category: Respiratory Medicine Source Type: research
To demonstrate techniques to regulate and improve the safety and completeness of laparoscopic and robotic radical hysterectomy/radical trachelectomy (L-RH/RT+R-RH/RT=MI-RH/RT) for early invasive cervical cancer. We will present our techniques and skills as well as data on our long-term outcomes for MI-RH/RT patients.
Source: The Journal of Minimally Invasive Gynecology - Category: OBGYN Authors: Tags: Plenary 3: Oncology (3:05 PM – 4:05 PM) 3:45 PM Source Type: research
Uterine leiomyosarcoma (uLMS) is aggressive mesenchymal neoplasm and is associated with a high risk of recurrence and poor prognosis. The 5year overall survival rate is about 60% even in FIGO stage I disease. There is no firm evidence of chemotherapy, so surgical resection should be considered to control the disease in case of localized recurrence. We will report a case underwent total laparoscopic complete resection for recurrent mass involved sigmoid colon and right ureter.
Source: The Journal of Minimally Invasive Gynecology - Category: OBGYN Authors: Tags: Plenary 3: Oncology (3:05 PM – 4:05 PM) 3:35 PM Source Type: research
To investigate the long term oncological follow up results and the relevant clinicopathologic prognostic factors for early stage (St IB1) cervical carcinoma patients who were surgically treated with Robot Assisted Radical Hysterectomy (RARH) or Open Radical Hysterectomy (ORH) from 2005 to 2012 at The Norwegian Radium Hospital.
Source: The Journal of Minimally Invasive Gynecology - Category: OBGYN Authors: Tags: Plenary 3: Oncology (3:05 PM – 4:05 PM) 3:25 PM Source Type: research
To compare the CareMe-Plus methylation and colposcopy biopsy to triage patients who test HPV-positive or abnormal LBC results for further treatment.
Source: The Journal of Minimally Invasive Gynecology - Category: OBGYN Authors: Tags: Plenary 3: Oncology (3:05 PM – 4:05 PM) 3:15 PM Source Type: research
More News: Anemia | Aplastic Anemia | Blogging | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Childhood Cancer | Clinical Trials | Economics | Environmental Health | Health | Health Management | Hodgkin's Disease | Hospitals | Lessons | Leukemia | Lymphoma | Men | Palliative | Palliative Care | Politics | Prostate Cancer | Radiation Therapy | Stem Cell Therapy | Stem Cells | Study | Transplant Surgery | Transplants | Women | Yale